This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hot Biotech Stocks Traded By Hedge Funds in Third Quarter

With those caveats in mind, Perceptive Advisors was the largest buyer of Sarepta in the third quarter, adding 1.4 million shares. Wellington Management also bought 1 million shares.

BlackRock was a notable (perhaps regretful) Sarepta seller, shedding 8.5 million shares across two different entities, according to Whale Wisdom.

For Arena Pharmaceuticals (ARNA - Get Report), three new buyers of note during the third quarter, which began right before the approval of the company's weight-loss pill Belviq: Deerfield Management (7.8 million shares), Capital World Investors (5 million shares) and QVT Financial (2.7 million shares)

Blackrock sold 9.9 million Arena shares during the third quarter. There was also significant net-selling options activity in Arena from Susequehanna International, Barclays, Group One Trading and Citigroup, according to Whale Wisdom.

Spectrum Pharmaceuticals (SPPI - Get Report) lost Tang Capital as a major shareholder in the third quarter. The San Diego-based hedge fund sold 4 million Spectrum shares, retaining 1.5 million shares.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMRN $1.54 -6.70%
ARNA $1.58 0.32%
SPPI $6.98 9.10%
SRPT $17.15 2.30%
AAPL $92.40 -0.90%


Chart of I:DJI
DOW 17,685.39 +24.68 0.14%
S&P 500 2,046.99 -3.64 -0.18%
NASDAQ 4,701.3840 -15.71 -0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs